Clinical application and observation of 5G remote robotic radical gastrectomy for gastric cancer
摘要
To evaluate the safety and short-term efficacy of 5G remote robotic surgery in radical gastrectomy for gastric cancer, with a focus on technical feasibility and perioperative outcomes.
MethodsA retrospective analysis was conducted on ten cases of 5G remote robotic radical gastrectomy for gastric cancer performed between May 2023 and November 2024 at Gansu Provincial Hospital in collaboration with the Affiliated Hospital of Yangzhou University and the New District Branch of Gansu Provincial Hospital. Primary endpoints included intraoperative network latency, operative duration, estimated blood loss, D2 lymphadenectomy adequacy, Clavien–Dindo complication grade, and R0 resection rate, and other indicators.
ResultsNetwork Parameters: For procedures with a communication distance of 1758 km (n = 5), the median (interquartile range, IQR) network latency was 91 (70–100) ms; for those with a distance of 63 km (n = 5), the median (IQR) latency was 51 (46–71.5) ms. No obvious abnormalities in the network connection. Surgical outcomes: Total gastrectomy (n = 3) had a median of 285 min (IQR 265–320), while distal gastrectomy (n = 7) had a median of 230 min (IQR 200–260). Estimated intraoperative blood loss 35 ± 13.44 mL. One patient required 3 units RBC transfusion for preoperative anemia. Conversion to open surgery rate was 0%. Complications: All postoperative complications were ≤ Clavien–Dindo Grade II, with no severe adverse events. Pathological Results: The number of dissected lymph nodes was 32.8 ± 7.08, the number of positive lymph nodes was 2.9 ± 3.81, and the R0 resection rate was 100%.
This study preliminarily confirms that 5G remote robotic radical gastrectomy is technically feasible and has good short-term safety. Despite the limitation of a small sample size, its results provide a reference for conducting pilot studies on remote surgery. In the future, larger-scale, long-term follow-up-controlled studies will be needed to further verify its clinical value and cost-effectiveness.